Viewing Study NCT03536208



Ignite Creation Date: 2024-05-06 @ 11:30 AM
Last Modification Date: 2024-10-26 @ 12:46 PM
Study NCT ID: NCT03536208
Status: WITHDRAWN
Last Update Posted: 2021-03-25
First Post: 2018-03-28

Brief Title: Biological Effect of Warfarin on Pancreatic Cancer
Sponsor: University of Texas Southwestern Medical Center
Organization: University of Texas Southwestern Medical Center

Study Overview

Official Title: Biological Effect of Warfarin on Pancreatic Cancer
Status: WITHDRAWN
Status Verified Date: 2021-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: no accrual for over 12 months
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study aims to asses the effect of warfarin on markers of AXL pathway in patients with pancreatic adenocarcinoma
Detailed Description: There is emerging evidence from pre-clinical models that Axl activation is critical for the tumorigenesis and metastasis of pancreatic cancer Warfarin is a readily available drug in the clinical setting and could be easily safely and quickly used in patients in combination with known cytotoxic chemotherapies to improve overall survival

Oral warfarin has been well tolerated in both prophylaxis for catheter-associated thrombosis and in advanced pancreatic cancer patients

The aim of this trial is to confirm the preclinical evidence that warfarin affects AXL pathway in patients with pancreatic cancer This will validate the effect of escalating doses of warfarin on circulating biomarkers of AXL

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: False
Is an FDA AA801 Violation?: None